This seemed to be opposite to the results reported by Ligorio et al. and Araki et al., who found that the pan-immune-inflammatory value or baseline absolute lymphocyte count, but not the NLR, was significantly associated with the prognosis of HER2-positive advanced BC patients treated with trastuzumab plus pertuzumab [22, 23]. Here, ERBB2 is linked to breast cancer.